The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
NGM Biopharmaceuticals Inc | COM | 62921N105 | 28,837,409 | 18,136,735 | SH | SOLE | 18,136,735 | 0 | 0 | ||
ORIC Pharmaceuticals Inc. | COM | 68622P109 | 48,685,684 | 3,540,777 | SH | SOLE | 3,540,777 | 0 | 0 | ||
RAPT Therapeutics Inc | COM | 75382E109 | 24,071,977 | 2,680,621 | SH | SOLE | 2,680,621 | 0 | 0 | ||
Revolution Medicines Inc | COM | 76155X100 | 1,483 | 46 | SH | SOLE | 46 | 0 | 0 | ||
Surrozen, Inc. | COM | 86889P109 | 9,685,843 | 616,540 | SH | SOLE | 616,540 | 0 | 0 | ||
Tenaya Therapeutics, Inc. | COM | 87990A106 | 49,163,517 | 9,400,290 | SH | SOLE | 9,400,290 | 0 | 0 | ||
Sagimet Biosciences Inc. | COM | 786700104 | 93,056 | 17,169 | SH | SOLE | 17,169 | 0 | 0 |